Stenberg D, Salvén P, Miettinen M V
Department of Physiology, University of Helsinki, Finland.
J Vet Pharmacol Ther. 1987 Dec;10(4):319-23. doi: 10.1111/j.1365-2885.1987.tb00108.x.
Medetomidine, a novel alpha 2-agonist drug intended for small animal sedation, was injected intramuscularly at dose rates of 0.02, 0.06 and 0.18 mg/kg. Xylazine (3.0 mg/kg) and saline were used for comparison. The five treatments were tested in a Latin square design in five cats. Treatments differed significantly in three-way analysis of variance, medetomidine inducing an increase in drowsiness with a corresponding decrease in both aroused waking and sleep determined by polygraphical criteria. The duration of effect was dose-dependent. The effect of 0.18 mg/kg medetomidine was comparable to 3.0 mg/kg of xylazine. The drugs also induced bradycardia.
美托咪定是一种用于小动物镇静的新型α2 激动剂药物，以0.02、0.06和0.18mg/kg的剂量率进行肌肉注射。使用赛拉嗪（3.0mg/kg）和生理盐水作为对照。在五只猫身上采用拉丁方设计对这五种处理进行了测试。在三因素方差分析中，各处理之间存在显著差异，美托咪定可导致嗜睡增加，同时根据多导记录标准，觉醒和睡眠状态均相应减少。作用持续时间呈剂量依赖性。0.18mg/kg美托咪定的效果与3.0mg/kg赛拉嗪相当。这些药物还会引起心动过缓。
